MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Search

Twist Bioscience Corp

Geschlossen

BrancheGesundheitswesen

37.83 -1.64

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

37.44

Max

38.24

Schlüsselkennzahlen

By Trading Economics

Einkommen

-7.7M

-39M

Verkäufe

4.1M

93M

Gewinnspanne

-42.383

Angestellte

923

EBITDA

-21M

-46M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+20.22% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

1. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-54M

2.3B

Vorheriger Eröffnungskurs

39.47

Vorheriger Schlusskurs

37.83

Nachrichtenstimmung

By Acuity

100%

0%

363 / 376 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Twist Bioscience Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

11. Juli 2025, 22:19 UTC

Akquisitionen, Fusionen, Übernahmen

FCC Approves U.S. Cellular Sale to T-Mobile

11. Juli 2025, 17:28 UTC

Wichtige Markttreiber

SharpLink Gaming Gains on Ethereum Purchase

11. Juli 2025, 16:57 UTC

Ergebnisse

BASF Cuts Outlook on Global Economy Uncertainty

11. Juli 2025, 21:45 UTC

Market Talk

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11. Juli 2025, 19:46 UTC

Akquisitionen, Fusionen, Übernahmen

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11. Juli 2025, 19:45 UTC

Market Talk

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11. Juli 2025, 19:05 UTC

Market Talk

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11. Juli 2025, 18:18 UTC

Market Talk

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11. Juli 2025, 17:35 UTC

Market Talk

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11. Juli 2025, 17:26 UTC

Market Talk

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11. Juli 2025, 16:53 UTC

Market Talk

Crude Futures Add to Early Gains -- Market Talk

11. Juli 2025, 16:42 UTC

Ergebnisse

BASF Cuts Outlook on Global Economic Uncertainty

11. Juli 2025, 16:08 UTC

Market Talk

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11. Juli 2025, 16:05 UTC

Ergebnisse

BASF Will Publish Half-Year Results on July 30

11. Juli 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

11. Juli 2025, 16:04 UTC

Market Talk

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

11. Juli 2025, 16:03 UTC

Ergebnisse

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

11. Juli 2025, 16:02 UTC

Ergebnisse

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

11. Juli 2025, 16:01 UTC

Ergebnisse

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

11. Juli 2025, 16:00 UTC

Ergebnisse

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

11. Juli 2025, 15:59 UTC

Ergebnisse

BASF Cuts 2025 Earnings View

11. Juli 2025, 15:58 UTC

Ergebnisse

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

11. Juli 2025, 15:57 UTC

Ergebnisse

BASF 2Q EBIT Before Special Items EUR810M

11. Juli 2025, 15:54 UTC

Ergebnisse

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

11. Juli 2025, 15:54 UTC

Ergebnisse

BASF 2Q Sales Fell 2.1% on Year

11. Juli 2025, 15:53 UTC

Ergebnisse

BASF 2Q Sales EUR15.77B

11. Juli 2025, 15:52 UTC

Ergebnisse

BASF: This Was in Line With Consensus Estimates

11. Juli 2025, 15:52 UTC

Ergebnisse

BASF 2Q Ebitda Before Special Items EUR1.77B

11. Juli 2025, 15:49 UTC

Ergebnisse

BASF Reports Preliminary 2Q Figures, Adjusts 2025 Outlook

11. Juli 2025, 15:41 UTC

Market Talk

Oil, Gas Prices Not Seen Supporting Drilling Boom -- Market Talk

Peer-Vergleich

Kursveränderung

Twist Bioscience Corp Prognose

Kursziel

By TipRanks

20.22% Vorteil

12-Monats-Prognose

Durchschnitt 46.25 USD  20.22%

Hoch 62 USD

Tief 33 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Twist Bioscience Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

9 ratings

6

Buy

2

Halten

1

Sell

Technischer Score

By Trading Central

31.56 / 38.6884Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

363 / 376 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.